Allogene Therapeutics Inc (ALLO)
Allogene Therapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology. The company develops and seeks to commercialize genetically engineered allogeneic T cell therapies for cancer and autoimmune diseases, with an emphasis on CAR T cell product candidates built using protein engineering, gene editing, gene insertion, and proprietary T cell manufacturing technologies. Its development pipeline includes cemacabtagene ansegedleucel, or cema-cel, a CD19-targeted candidate being studied for large B-cell lymphoma; ALLO-316, a CD70-targeted candidate for renal cell carcinoma; and ALLO-329, a dual CD19/CD70 candidate for autoimmune diseases such as systemic lupus erythematosus, idiopathic inflammatory myopathies, and systemic sclerosis. Incorporated in 2017, the company is headquartered in South San Francisco, California, and its common stock trades on NASDAQ under the symbol ALLO.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ALLO
|
$1.73
|
-4.8% Downside
|
Fair
|
$9
|
395.9% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 5, 2026
|
-3.6x
|
2.2x
|
—
|
610.9 M
|
440.6 M
|
11.7%
|
78.4%
|
-5.0
|
—
|
63.0%
|
